e-learning
resources
Virtual 2020
Pre-Congress Content
Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cluster analysis and survival in patients with Idiopathic pulmonary fibrosis
D. Kalafatis (Stockholm, Sweden), L. Carlson (Stockholm, Sweden), J. Gao (Stockholm, Sweden), C. Li (Stockholm, Sweden), I. Pesonen (Stockholm, Sweden), C. Sköld (Stockholm, Sweden)
Source:
Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Session:
Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Session type:
E-poster session
Number:
1840
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Kalafatis (Stockholm, Sweden), L. Carlson (Stockholm, Sweden), J. Gao (Stockholm, Sweden), C. Li (Stockholm, Sweden), I. Pesonen (Stockholm, Sweden), C. Sköld (Stockholm, Sweden). Cluster analysis and survival in patients with Idiopathic pulmonary fibrosis. 1840
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study
Source: Eur Respir J 2012; 40: 101-109
Year: 2012
Idiopathic pulmonary fibrosis: Gender differences in survival and functional decline. A retrospective study
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Survival predictors in a cohort of patients with idiopathic pulmonary fibrosis biopsy-proven
Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV
Year: 2012
Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Idiopathic pulmonary upper lobe fibrosis shows distinct features and poor prognosis compared to idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 246s
Year: 2007
Idiopathic pulmonary fibrosis: Relationship between patient survival and distance-saturation product
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Genetic predictors of idiopathic pulmonary fibrosis (IPF) prognosis
Source: Eur Respir J 2006; 28: Suppl. 50, 830s
Year: 2006
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Biopsy documented idiopathic interstitial pneumonias - Analysis of diagnostic yield, survival and mortality over 9 years
Source: Annual Congress 2013 –Interventional procedures for diagnosis of diffuse lung diseases and peripheral pulmonary lesions
Year: 2013
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
Median survival in unselected patients with idiopathic pulmonary fibrosis in the United Kingdom
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Real life experience with nintedanib in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Idiopathic pulmonary fibrosis (IPF): the patient journey
Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Year: 2020
Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Onset of symptoms in idiopathic pulmonary fibrosis: A case-control study
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept